Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis

Immunology

Volumn 116, Issue 1, 2005, Pages 21-29

  Takata Tomokuni, Akiko ^a   Ueki, Ayako ^a   Shiwa, Mieko ^b   Isozaki, Yumika ^a   Hatayama, Tamayo ^a   Katsuyama, Hironobu ^a   Hyodoh, Fuminori ^a   Fujimoto, Wataru ^a   Ueki, Hiroaki ^a   Kusaka, Masayasu ^c   Arikuni, Hisashi ^b   Otsuki, Takemi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Ciphergen Biosystems Inc   (Japan)

^c Kusaka Hospital   (Japan)

Author keywords

Anti Fas autoantibody; Autoimmune diseases; Silicosis; siRNA

Indexed keywords

AMINO ACID; EPITOPE; FAS ANTIBODY; FAS ANTIGEN; SMALL INTERFERING RNA;

ADOLESCENT; ADULT; AGED; AMINO ACID ANALYSIS; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SILICOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; AMINO ACIDS; ANTIGENS, CD95; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BLOTTING, WESTERN; CELL DIVISION; EPITOPE MAPPING; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; RNA, SMALL INTERFERING; SCLERODERMA, SYSTEMIC; SILICOSIS; TUMOR CELLS, CULTURED;

EID: 23944439106     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2005.02192.x     Document Type: Article

References (28)

1. Tomokuni A, Aikoh T, Matsuki T et al. Elevated soluble Fas/ APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol 1997; 110:303.
2. Otsuki T, Sakaguchi H, Tomokuni A et al. Soluble Fas mRNA is dominantly expressed in cases with silicosis. Immunology 1998; 94:258.
3. Tomokuni A, Otsuki T, Sakaguchi H, Isozaki Y, Hyodoh F, Kusaka M, Ueki A. Detection of anti-topoisomerase I autoantibody in patients with silicosis. Environ Health Prev Med 2002; 7:7.
4. Ueki H, Kohda M, Nobutoh T et al. Antidesmoglein autoantibodies in silicosis patients with no bullous diseases. Dermatology 2001; 202:16.
5. Ueki A, Isozaki Y, Tomokuni A et al. Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals. Clin Exp Immunol 2002; 129:556.
6. Frank R. Spot synthesis, an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 1992; 48:9217.
7. Austen BM, Frears ER, Davies H. The use of seldi proteinchip arrays to monitor production of Alzheimer's betaamyloid in transfected cells. J Pept Sci 2000; 6:459.
8. International Labour Organization (ILO) Guidelines for the Use of the ILO International Classification of Radiographs of Pneumoconioses, Revised Edn. Geneva, Switzerland: ILO Publications, 2000.
9. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271.
10. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581.
11. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M, Namba M. Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol 1989; 73:199.
12. Otsuki T, Hata H, Harada N et al. Cellular biological differences between human myeloma cell lines KMS-12-PE and KMS-12-BM established from a single patient. Int J Hematol 2000; 72:216.
13. Otsuki T, Yamada O, Sakaguchi H, Tomokuni A, Wada H, Yawata Y, Ueki A. Human myeloma cell apoptosis induced by interferon-alpha. Br J Haematol 1998; 103:518.
14. Fadeel B, Thorpe J, Chiodi F. Mapping of the linear site on the Fas/APO-1 molecule targeted by the prototypic anti-Fas mAb. Int Immunol 1995; 7:1967.
15. Otsuki T, Yamada O, Kurebayashi J et al. Estrogen receptors in human myeloma cells. Cancer Res 2000; 60:1434.
16. Starling GC, Bajorath J, Emswiler J, Ledbetter JA, Aruffo A, Kiener PA. Identification of amino acid residues important for ligand binding to Fas. J Exp Med 1997; 185:1487.
17. Schneider P, Bodmer JI, Holler N, Mattmann C, Scuderi P, Terskikh A, Peitsch MC, Tschopp J. Characterization of Fas (Apo-1, CD95) -Fas ligand interaction. J Biol Chem 1997; 272:18827.
18. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 1999; 103:355.
19. Orlinick JR, Vaishnaw A, Elkon KB, Chao MV. Requirement of cysteine-rich repeats of the Fas receptor for binding by the Fas ligand. J Biol Chem 1997; 272:28889.
20. Fadeel B, Thorpe CJ, Yonehara S, Chiodi F. Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro. Int Immunol 1997; 9:201.
21. Fadeel B, Lindberg J, Achour A, Chiodi F. A three-dimensional model of the Fas/APO-1 molecule: cross-reactivity of anti-Fas antibodies explained by structural mimicry of antigenic sites. Int Immunol 1998; 10:131.
22. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74:845.
23. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993; 268:10932.
24. Boldin MP, Mett IL, Varfolomeev EE, Chumakov I, ShemerAvni Y, Camonis JH, Wallach D. Self association of the 'death domains' of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem 1995; 270:387.
25. Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996; 384:638.
26. Berglund H, Olerenshaw D, Sankar S, Federwisch M, McDonald NQ, Driscoll PC. The three-dimensional solution structure and dynamic properties of the human FADD death domain. J Mol Biol 2000; 302:171.
27. Yi FH, Lautrett C, Vermot-Desroches C, Bordessoule D, Couratier F, Wijdenes J, Preud'homme JL, Jauberteau MO. In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients. J Neuroimmunol 2000; 109:211.
28. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkin MD, Ruberti G, Kaveri SV. Therapeutic preparations of normal poly-specificIgG (IVIg) induce apoptosis in human lymphocytes and monocytes. a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161:3781.